Skip to main content
. Author manuscript; available in PMC: 2021 Sep 29.
Published in final edited form as: Menopause. 2021 Jul 26;28(10):1125–1129. doi: 10.1097/GME.0000000000001823

Table 2.

Associations of Estrogen Subtypes with Risk of Incident Venous thromboembolism

Incidence
 Hazard Ratios
Events Person
Years / 1000		 Incidence Rate
per 1000PY		 Unadjusted
(95%CI)		 Age Adjusted
(95%CI)		 Fully Adjusteda
(95%CI)
PRIMARY ANALYSIS
Oral CEE 165 85.1 1.94 Ref Ref Ref
Oral E2 27 15.6 1.73 0.89
(0.59-1.33)		 0.97
(0.64-1.46)		 0.96
(0.64-1.46)
Transdermal E2 22 13.3 1.65 0.85
(0.55-1.33)		 0.95
(0.60-1.48)		 0.95
(0.60-1.49)
RESTRICTED TO INCIDENT(NEW) USERS
CEE Oral 47 28.8 1.63 Ref Ref Ref
E2 Oral 11 7.8 1.41 0.85
(0.44-1.65)		 0.86
(0.44-1.66)		 0.83
(0.42-1.62)
E2 Transdermal 11 6.6 1.66 1.02
(0.53-1.97)		 1.03
(0.53-1.99)		 1.02
(0.52-1.99)
a

Adjusted for age, race, and BMI; stratified by previous use of HT, and progestogen use

BMI = body mass index ; HT = hormone therapy ; CEE = conjugated equine estrogens ; E2 = estradiol